BMJ vs Clinical Infectious Diseases: Which Journal Should You Choose?

The BMJ asks whether the ID paper matters to a broad clinical or policy audience. CID asks whether it changes infectious-disease practice.

That's the real submission decision.

If the manuscript becomes more persuasive when written for ID clinicians who care about stewardship, diagnostics, immunocompromised hosts, outbreak management, or therapeutic decisions inside the field, CID usually becomes the better home. If the paper becomes stronger when framed as a broad clinical or systems argument, The BMJ becomes more realistic.

The BMJ wins when the infectious-disease study behaves like a broad clinical or policy paper.

That usually means:

• policy-relevant outbreak or systems studies
• stewardship or resistance work with broad health-system consequences
• care-delivery or implementation papers that matter beyond ID
• a manuscript that gets stronger when written for general clinicians

BMJ's editorial guidance repeatedly emphasize policy consequence, broad clinical relevance, and clear practice meaning for a wide readership.

CID wins when the paper is strongest as a clinician-facing infectious-disease manuscript.

That includes:

• antimicrobial resistance and stewardship papers
• diagnostic studies with real practice consequences
• treatment and prevention studies
• immunocompromised-host and transplant infection work
• pathogen-specific or outbreak papers whose strongest readers are still ID specialists

CID fit and submission's editorial guidance are unusually clear that papers need to change diagnosis, treatment, prevention, or patient management.

The journal's editorial guidance names these as the journal's core editorial lanes. That helps separate clinically useful ID papers from microbiology-heavy or descriptive work that's weaker for CID.

When the paper is really about system-level change, health policy, or broad implementation consequences, The BMJ can be more natural than a specialist ID title.

A manuscript can stay rooted in infectious-disease practice there, as long as the clinical consequence is strong. The BMJ is less willing to carry that same specialist setup unless the implications are clearly broad.

If the paper only fully lands for ID clinicians, the general-medical case weakens quickly.

• the paper has visible importance beyond infectious disease
• the result changes broad clinical practice, systems thinking, or policy
• non-ID clinicians should care immediately
• the manuscript becomes stronger when generalized for broad medicine

That's the narrower lane.

• the real audience is still infectious-disease practice
• the paper changes diagnosis, treatment, prevention, or stewardship
• the manuscript is strongest as a clinician-facing ID paper
• the study depends on ID-specific interpretation
• broadening the paper too far would weaken it

That's often the cleaner first move.

This is a sensible cascade.

If The BMJ rejects the manuscript because it's too specialty-defined, CID can be a strong next move.

That works especially well when:

• the science is strong
• the main weakness was breadth, not rigor
• the manuscript already reads naturally as an ID paper
• the practical consequence for clinicians is obvious

It works less well when the study is too descriptive or weak on patient-facing relevance. BMJ rejection for fit can still point to CID. BMJ rejection for thin practical value usually won't.

If the manuscript's real audience is only ID clinicians, editors usually see the mismatch early.

The journal's editorial guidance says this repeatedly. Interesting data aren't enough if the paper doesn't change infectious-disease decision-making.

Editors need to see quickly why the paper matters outside the specialty.

Laboratory-heavy or descriptive studies without a strong management consequence often struggle.

These are often cleaner CID papers unless the systems consequences are broad enough to justify a BMJ audience.

These usually favor CID when the practical readers are still ID clinicians.

These can favor The BMJ when the paper is really about broad systems change.

This category can go either way. If the practical audience is still ID, CID usually wins. If the policy implications dominate, The BMJ becomes more plausible.

A strong BMJ first page usually makes the broad clinical or policy consequence obvious immediately. The reader shouldn't need much ID-specific setup before the importance lands.

A strong CID first page can assume more specialty context, but it still has to show quickly what changes in diagnosis, treatment, prevention, or management.

That distinction is often visible before submission.

Ask which sentence fits the paper better:

• "this changes what clinicians or policymakers broadly should do or think" points toward The BMJ
• "this changes what infectious-disease clinicians should do or think" points toward Clinical Infectious Diseases

That sentence is often more useful than comparing title prestige.

CID can be the better strategic choice when the manuscript's value depends on:

• stewardship or resistance context
• diagnostic and treatment decision-making
• immunocompromised-host or pathogen-specific interpretation
• readers who already think in infectious-disease clinical frameworks

In those cases, forcing the paper toward The BMJ can blur the strongest parts of the manuscript.

Send to The BMJ first if:

1. the paper has clear importance beyond infectious disease
2. a broad clinical or policy audience should care immediately
3. the manuscript becomes more powerful when framed for general medicine

Send to Clinical Infectious Diseases first if:

1. the real audience is still infectious-disease practice
2. the paper changes diagnosis, treatment, prevention, or stewardship
3. the study depends on ID-specific interpretation
4. the paper loses force when generalized too far